SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-QSB
-------------------------------------------------------
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1998
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____
Commission File number 0-22146
APPLIED BIOMETRICS, INC.
(Exact name of small business issuer as specified in its charter)
Minnesota 41-1508112
-------------------------------------------------------
(State of other jurisdiction of (I.R.S. Employer
Incorporation or organization) Identification No.)
501 E. Highway 13, Burnsville, MN 55337
-------------------------------------------------------
(Address of principal executive office and zip code)
Issuer's telephone number, including area code (612) 890-1123
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for at least the past 90 days.
Yes __X__ No _____
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
At April 26, 1998, there were outstanding 4,296,117 shares of common
stock, $0.01 par value.
<PAGE>
APPLIED BIOMETRICS, INC.
Form 10-QSB Index
March 31, 1998
Part I: Financial Information.........................................3
Item 1. Financial Statements..........................................3
Balance Sheets Unaudited at March 31, 1998
and Audited at December 31, 1997..............................3
Unaudited Statement of Operations for the Three
Month Periods ended March 31, 1998 and 1997...................4
Statement of Shareholders' Equity for
year ended December 31, 1997 and for
the Unaudited Three Months Period ended March 31, 1998........5
Unaudited Statement of Cash Flows for the
Three Month Periods Ended March 31, 1998
and 1997......................................................6
Notes to Unaudited Financial Statements.......................7
Item 2. Management's Discussion and Analysis
Or Plan of Operation..........................................8
Part II: Other Information.............................................10
Item 1. Legal Proceedings.............................................10
Item 2. Changes in Securities.........................................10
Item 3. Defaults Upon Senior Securities...............................10
Item 4. Submission of Matters to a Vote of
Security Holders..............................................10
Item 5. Other Information.............................................10
Item 6. Exhibits and Reports of Form 8-K..............................10
Signatures ..............................................................11
<PAGE>
Part 1: Financial Information
Item 1. Financial Statements
APPLIED BIOMETRICS, INC.
Balance Sheets
<TABLE>
<CAPTION>
March 31,
1998 December 31,
(Unaudited) 1997
------------ ------------
<S> <C> <C>
ASSETS
Current Assets
Cash and cash equivalents 993,685 821,673
Short-term investments 2,944,967 3,598,507
Accounts Receivable 20,490 --
Inventory 146,769 150,493
Prepaid expensed and other current assets 96,577 86,166
------------ ------------
TOTAL CURRENT ASSETS 4,202,488 4,656,839
Property and equipment, net 565,538 571,374
Patents, net 193,663 200,125
Other assets 9,585 9,585
------------ ------------
TOTAL ASSETS $ 4,971,274 $ 5,437,923
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Trade accounts payable 78,321 76,042
Accrued expenses and other liabilities 96,158 90,679
------------ ------------
TOTAL CURRENT LIABILITIES 174,479 166,721
SHAREHOLDERS' EQUITY
Common stock, $.01 par value,
10,000,000 shares authorized:
4,296,117 and 4,276,117 shares issued
and outstanding at March 31, 1998 and
December 31, 1997, respectfully 42,961 42,761
Additional paid-in-capital 20,371,259 20,278,959
Accumulated deficit (15,617,425) (15,050,518)
------------ ------------
TOTAL SHAREHOLDERS' EQUITY 4,796,795 5,271,202
TOTAL LIABILITIES AND SHAREHOLDER'S EQUITY $ 4,971,274 $ 5,437,923
============ ============
</TABLE>
<PAGE>
APPLIED BIOMETRICS, INC.
Statement of Operations
(Unaudited)
Three Months Ended
----------------------------
March 31, March 31,
1998 1997
----------- -----------
Net Sales $ 20,490 $ 56,070
Cost of Sales 4,098 26,850
----------- -----------
Gross Profit 16,392 29,220
----------- -----------
Operating Expenses:
Research and Development 319,036 319,448
Sales and Marketing 145,662 72,197
General and Administrative 176,005 163,593
----------- -----------
Total Operating Expenses 640,703 555,238
----------- -----------
Operating loss (624,311) (526,018)
Interest income 57,404 84,176
----------- -----------
Net Loss $ (566,907) $ (441,842)
=========== ===========
Loss per common share:
Basic $ (.13) $ (.11)
=========== ===========
Diluted $ (.13) $ (.11)
=========== ===========
Weighted average common shares 4,281,228 4,169,487
outstanding =========== ===========
<PAGE>
APPLIED BIOMETRICS, INC.
Statement of Shareholders' Equity
<TABLE>
<CAPTION>
Additional
Common Stock Paid-In Accumulated
Shares Amount Capital Deficit
<S> <C> <C> <C> <C>
December 31, 1996 4,168,987 $ 41,690 $ 19,703,468 $(12,458,048)
Shares issued for purchase of
transcatheter closure product line 85,000 850 509,150
Exercise of stock options 22,130 221 66,341
1997 Net Loss (2,592,470)
------------ ------------ ------------ ------------
December 31, 1997 4,276,117 42,761 20,278,959 (15,050,518)
Exercise of stock options
(unaudited)
20,000 200 92,300
Net loss three months ended
March 31, 1998 (unaudited) (566,907)
------------ ------------ ------------ ------------
March 31, 1998 (unaudited) 4,296,117 42,961 20,371,259 $(15,617,425)
============ ============ ============ ============
</TABLE>
<PAGE>
APPLIED BIOMETRICS, INC.
Statement of Cash Flows
(Unaudited)
<TABLE>
<CAPTION>
Three Months Ended
----------------------------
March 31, March 31,
1998 1997
----------- -----------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss $ (566,907) $ (441,842)
Adjustments to reconcile net loss to net
cash provided by operating activities:
Depreciation and amortization 58,896 41,406
Cash flows provided by (used for) changes in:
Accounts receivables (20,490) (20,857)
Inventory 3,724 (10,014)
Prepaid expenses and other assets (10,411) 37,661
Accounts payable 2,279 27,366
Accrued expenses and other liabilities 5,479 13,887
----------- -----------
Net cash flows used by operating activities (527,430) (352,393)
----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Sales and maturities of short term investments 653,540 1,750,370
Purchases of short-term investments -- (1,135,713)
Purchase of property and equipment (46,598) (74,150)
----------- -----------
Net cash used in investing activities 606,942 540,507
----------- -----------
CASH FLOW FROM FINANCING ACTIVITIES:
Exercise of options and warrants 92,500 3,000
----------- -----------
Net cash provided by financing activities 92,500 3,000
----------- -----------
Net (decrease) increase in cash and
cash equivalents 172,012 191,114
CASH AND CASH EQUIVALENTS:
Beginning of period 821,673 741,661
----------- -----------
End of period $ 993,685 $ 932,775
=========== ===========
</TABLE>
<PAGE>
APPLIED BIOMETRICS, INC.
NOTES TO UNADUITED FINANCIAL STATEMENTS
Note 1. Unaudited Interim Results
The accompanying unaudited financial statements have been prepared in accordance
with the instructions to Form 10-QSB and do not include all the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair presentation have
been included.
Operating results for the three months ended March 31, 1998 are not necessarily
indicative of the results that may be expected for the year 1998.
These statements should be read in conjunction with the audited financial
statements and related notes for the year ended December 31, 1998 included in
the Company's Form 10-KSB for the year ended December 31, 1997.
Note 2. Purchase of Product Line
In November 1997, the Company acquired the technology and assets (including the
in-process research and development) of the transcatheter closure product line
of Schneidt Implantate, GmbH of Frankfurt, Germany. The total purchase price was
$541,457 which included 85,000 shares of common stock, and $31,457 of
acquisition related costs. The assets acquired consisted exclusively of patents
and other intangibles. The in-process research and development costs of $441,457
were charged against income in 1997, as the underling research and development
projects had not yet reached technologic feasibility.
<PAGE>
Item 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
RESULTS OF OPERATIONS
For the three months ended March 31, 1998 and 1997.
NET SALES. For the three months ended March 31, 1998 the Company had net sales
of $20,490 compared to $56,070 for the three months ended March 31, 1997. Sales
in the first quarter of 1998 are from the initial shipments of the transcatheter
closure product line that was acquired in November 1997. The Company expects
these sales to increase during subsequent quarters in 1998. The sales in the
first quarter of 1997 were from the Company's cardiac output monitoring system.
There were no sales of this system in the first quarter of 1998 as a result of
the Company making a strategic decision in the third quarter of 1997 not to
continue marketing its cardiac output monitoring system until completion of the
development of the next generation system. The new system is presently
undergoing lab and clinical testing and is expected to be available to the
market upon successful completion of the testing sometime during 1998. The
Company believes that because of the early stage of its sales, that its revenues
will continue to fluctuate in future periods.
GROSS PROFIT. The Company's gross profit margin as a percentage of net sales was
80.0% for the three months ended March 31, 1998 compared to 52.1% for the three
months ended March 31,1997. The increase in gross margins in the first quarter
of 1998 is a result of the Company's transcatheter closure device having a
higher gross margin then its cardiac output system. The Company believes that
these margins are not necessarily representative of the margins it will realize
in the future periods.
RESEARCH & DEVELOPMENT. Research and Development expenses were $319,036 for the
three months ended March 31, 1998 compared to $319,448 for the three months
ended March 31, 1997. Although the actual research and development expenditures
did not increase in 1998, the mix of expenditures changed. The cardiac output
monitoring system expenditures decreased slightly because the Company is nearing
the completion of the development of this system while the transcatheter closure
product line expenditures increased as the Company began the expansion of the
development of this product line.
SALES AND MARKETING. Sales and Marketing expenses increased 101.8% to $145,662
for the three months ended March 31, 1998 from $72,197 for the three months
ended March 31, 1997. This increase is the result of the following: (1)
increased personnel, (2) commencement of marketing of the transcatheter closure
device in Europe, (3) expenditures to obtain ISO 9000 certification and the CE
mark in Europe and, (4) expenditures to begin clinical trials of the
transcatheter product in the United States. The Company expects its sales and
marketing expenses to continue to increase in 1998 as it continues its
expenditures in these areas.
<PAGE>
GENERAL AND ADMINISTRATIVE. General and Administrative expenses increased 7.6%
to $176,005 for the three months ended March 31, 1998 from $163,593 for the
three months ended March 31, 1997. This increase was the result of increased
administrative expenses associated with a higher level of activity. General and
Administrative expenses are expected to increase slightly in 1998 as the
Company's business activity expands.
INTEREST INCOME. Interest income decreased 31.8% to $57,404 for the three months
ended March 31, 1998 from $84,176 for the three months ended March 31, 1997,
primarily as a result of fewer funds available for investment.
LIQUIDITY AND CAPITAL RESOURCES
At March 31, 1998, the Company has cash and short-term investments of $3,938,652
and working capital of $4,028,009. The Company used cash of $527,430 in
operating activity during first quarter of 1998 including a net loss of
$566,907. The Company generated funds to support this loss primarily through
sales and maturities of short-term investments in the amount of $653,540 and
$90,500 generated from the exercise of options and warrants.
The Company believes that its existing cash, cash equivalents and short-term
investments together with funds generated from operations will enable the
Company to meet its liquidity and capital needs for the next twelve months.
FORWARD LOOKING STATEMENTS
Statements included in this Form 10-QSB that are not historical in nature or
current facts are "forward-looking statements" made pursuant to the safe harbor
provisions of the Private Securities Reform Act of 1995 and are subject to
certain risks and uncertainties that could cause actual results to differ
materially. Among these risks and uncertainties are (1) the Company's limited
revenues, history of losses and uncertainty of future results, (2) the
uncertainty of market acceptance of the Company's products, and (3) the fact
that the Company has limited experience in manufacturing its products in
commercial quantities.
<PAGE>
PART II
OTHER INFORMATION
Item 1. Legal Proceedings
NONE
Item 2. Change in Securities
NONE
Item 3. Defaults Upon Senior Securities
NONE
Item 4. Submission of Matters to a Vote of Security Holders
NONE
Item 5. Other Information
NONE
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibit 27 - Financial Data Schedule
(b) No reports on Form 8-K were filed during the quarter
ended March 31, 1998.
<PAGE>
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Applied Biometrics, Inc.
-------------------------------
Registrant
/s/ Joseph A. Marino
-------------------------------
Joseph A. Marino
President, CEO
/s/ Gerald. J. Prescott
-------------------------------
Gerald J. Prescott
Vice President and
Chief Financial Officer
Date: May 4, 1998
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-END> MAR-31-1998
<CASH> 993,685
<SECURITIES> 2,944,967
<RECEIVABLES> 20,490
<ALLOWANCES> 0
<INVENTORY> 146,769
<CURRENT-ASSETS> 4,202,488
<PP&E> 1,041,315
<DEPRECIATION> (475,777)
<TOTAL-ASSETS> 4,971,274
<CURRENT-LIABILITIES> 174,479
<BONDS> 0
0
0
<COMMON> 42,961
<OTHER-SE> 4,753,834
<TOTAL-LIABILITY-AND-EQUITY> 4,971,274
<SALES> 20,490
<TOTAL-REVENUES> 20,490
<CGS> 4,098
<TOTAL-COSTS> 4,098
<OTHER-EXPENSES> 319,036
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (566,907)
<INCOME-TAX> 0
<INCOME-CONTINUING> (566,907)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (566,907)
<EPS-PRIMARY> (.13)
<EPS-DILUTED> (.13)
</TABLE>
